This document discusses optimal sequencing in metastatic castration-resistant prostate cancer (mCRPC). It presents several case studies and discusses the role of radiation, surgery, nuclear medicine, and systemic therapies. It then addresses questions about standard of care options for mCRPC, including chemotherapy, chemotherapy plus androgen deprivation therapy, chemotherapy plus antiandrogen therapy, and PARP inhibitors. Clinical trials evaluating treatments like cabazitaxel, abiraterone, and enzalutamide in mCRPC are also summarized.
Induction chemotherapy followed by concurrent ct rt versus ct-rt in advanced ...Santam Chakraborty
Small Presentation where the benefit of addition of induction / neoadjuvant chemotherapy to concurrent chemoradiation in head neck cancers is explored.
Overview about evolution of the term Oligometastases,the paradigm and various states of oligometastases,treat options ,clinical trials and relevance in current clinical practice
Induction chemotherapy followed by concurrent ct rt versus ct-rt in advanced ...Santam Chakraborty
Small Presentation where the benefit of addition of induction / neoadjuvant chemotherapy to concurrent chemoradiation in head neck cancers is explored.
Overview about evolution of the term Oligometastases,the paradigm and various states of oligometastases,treat options ,clinical trials and relevance in current clinical practice
advancements in the diagnostics help detect states like oligometastasis ,which can lead to selection of patients for local and MDT and prolong the time to adjuvant therapy, at present There is no consensus on the treatment of oligometastatic cancer and clinical trials can help in evidence formation.
Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor positive (HR+) early breast cancer (BC):
Chair and Presenter, Prof Eric Van Cutsem, MD, PhD, and Scott Kopetz, MD, PhD, prepared useful Practice Aids pertaining to colorectal cancer for this CME/MOC/NCPD activity titled “Putting a Personalized Colorectal Cancer Treatment Algorithm Into Practice: Navigating Practicalities in the Era of Molecularly Defined Care.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/NCPD information, and to apply for credit, please visit us at https://bit.ly/3aSSAtm. CME/MOC/NCPD credit will be available until November 13, 2022.
Report Back from San Antonio Breast Cancer Symposium (SABCS 2022)bkling
Curious about the latest developments in Early-Stage Breast Cancer and Metastatic Breast Cancer Research? Join us as Dr. Anne Blaes, the Division Director of Hematology/Oncology/Transplantation and Professor in Hematology/Oncology at the University of Minnesota, breaks down the most recent developments released at the annual San Antonio Breast Cancer Symposium regarding early-stage and metastatic breast cancer research.
advancements in the diagnostics help detect states like oligometastasis ,which can lead to selection of patients for local and MDT and prolong the time to adjuvant therapy, at present There is no consensus on the treatment of oligometastatic cancer and clinical trials can help in evidence formation.
Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor positive (HR+) early breast cancer (BC):
Chair and Presenter, Prof Eric Van Cutsem, MD, PhD, and Scott Kopetz, MD, PhD, prepared useful Practice Aids pertaining to colorectal cancer for this CME/MOC/NCPD activity titled “Putting a Personalized Colorectal Cancer Treatment Algorithm Into Practice: Navigating Practicalities in the Era of Molecularly Defined Care.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/NCPD information, and to apply for credit, please visit us at https://bit.ly/3aSSAtm. CME/MOC/NCPD credit will be available until November 13, 2022.
Report Back from San Antonio Breast Cancer Symposium (SABCS 2022)bkling
Curious about the latest developments in Early-Stage Breast Cancer and Metastatic Breast Cancer Research? Join us as Dr. Anne Blaes, the Division Director of Hematology/Oncology/Transplantation and Professor in Hematology/Oncology at the University of Minnesota, breaks down the most recent developments released at the annual San Antonio Breast Cancer Symposium regarding early-stage and metastatic breast cancer research.
Changing landscape in the treatment of advanced prostate cancer Alok Gupta
This presentation describes how the treatment of stage 4 prostate cancer has improved over last 100 years. This was presented at URO ONCOLOGY UPDATE meeting of Delhi Urological Society on 18th March 2017
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
8. QUESTIONS?
mHSPC- WHAT IS THE STANDARD OF CARE ?
1. CHEMO
2. ADT
3. CHEMO+ ADT
4. CHEMO+ CYP17A1 INHIBITORS
4. AR INHIBITORS
5. CHEMO+TAB
9. Dynamic Progression Model: Patient Flow Between Distinct Clinical States
9
PLoS One. 2015;10(10): e0139440
10. Metastatic Hormone Sensitive Prostate Cancer: mHSPC
10
Androgen Deprivation Therapy (ADT) has been mainstay of treatment
for advanced prostate cancer for > 60 years
We know that essentially all men will have rising PSA &/or develop new
metastases despite castrate levels of testosterone i.e. castration-
resistant prostate cancer (CRPC)
Does more potent upfront treatment of mHSPC improve outcomes?
o Non-AR mechanisms (docetaxel)
o AR driven (abiraterone, enzalutamide)
11. Spectrum of Patients
11
Spectrum of patients starting testosterone suppression for “metastatic”
disease
Some present de novo vs some present after prior prostatectomy or
radiation
Some are fit & young, some are frail & elderly
o & every iteration in between
Some have minimal disease on conventional scans and some
widespread disease
Some prior adjuvant testosterone suppression with radiation,
prostatectomy
o (+/- abiraterone; +/- docetaxel)
12. How to Decide on Treatment?
12
Treatment Considerations of mHSPC
De novo vs recurrent disease at presentation
Volume of disease
Co-morbidities
Side effect profiles
Patient preference
Cost
Availability of drug
13. Which Systemic Therapy for which Patient: Patient Profiles?
13
Docetaxel Abiraterone Enzalutamide
Chemo-fit , High volume
disease
Not chemo-fit, high volume
Not chemo-fit/ chemo-fit with
low volume denovo-METs
Not chemo-fit/ chemo-fit with
low volume prior therapy
Not chemo-fit, high volume
Not chemo-fit/ chemo-fit with
low volume denovo METs
Not chemo-fit/ chemo-fit
with low volume prior therapy
Denovo METs Skeletal METs Visceral METs (pre docetaxel )
Difficulty in swallowing
medicines
Poor diabetic control
Other contraindication with
prednisone
Heart failure or hypervolemia
Mild base line pain
Steroids may help
Significant baseline fatigue
Falls, gaits or neurological
disorder
Pre existing neuropathy
Fragile diabetes
Baseline edema
Hypokalemia
Pre existing neuropathy
Remote living
14. How we decide risk category of patient?
14
ADT + docetaxel
ADT + enzalutamide
ADT + abiraterone
What would be
your treatment plan?
Definition
CHAARTED
(Volume)
High
Visceral metastases AND/OR
≥4 Bone metastases (≥1 outside vertebral column or pelvis)
LATITUDE
(Risk)
High
≥2 high risk features
≥3 bone metastases
Visceral metastases
≥Gleason 8
15. Clinical evidences to direct treatment selection?
15
There are numerous Phase III studies supporting various therapeutic
combinations in metastatic hormone-sensitive prostate cancer:
TRIALS TREATMENT ARMS
CHAARTRED, STAMPEDE-C ADT VS ADT + DOCETAXEL
STAMPEDE-G , LATITUDE ADT VS ADT + ABIRATERONE
ARCHES, ENZAMET
ADT + DOCE VS ADT + (DOCE 17.9, 65%) +
ENZALUTAMIDE
TITAN
ADT (+ DOCE 10%) VS ADT (+ DOCE 10%) +
APALUTAMIDE
16. What are learnings from long term follow-up of CHAARTED?
16
Test for Heterogeneity
With long term
follow-up low
volume & high
volume had
differential effect
with early docetaxel
17. CHAARTED FACT-P: Quality of Life
17
Low-volume High-volume
ADT alone in low volume had no change in QOL over 12 months in low volume but
decline in high volume (progression of disease – symptoms and progression)
ADT plus docetaxel) decline in QOL in low vol on chemo But no decline and better 12
month QOL in high volume
19. Current Outcome with Docetaxel by Volume of Disease
Direct overall survival benefit for high volume patients in 2 studies
documented improvement in QOL
Two studies provide DIRECT evidence of no clear OS benefit in low
volume disease
Await retrospective volume analysis of STAMPEDE-docetaxel arm
o Will this translate into routine care (benefit less, toxicity including
treatment related deaths worse than in trials)
Volume is prognostic for outcome on ADT & predictive for docetaxel
benefit
o Does this mean there are different biological diseases in “mHSPC"?
19
20. STAMPEDE-docetaxel: Test for heterogeneity – M0 vs M1
20
M0 combines
o High risk localized treated with ADT +
XRT
o Rising PSA post local therapy
M1 combines
o Low & High Volume
LV benefit based on inference because
no difference on test of heterogeneity
between M0 & M1
23. Current Outcome with Abiraterone by Volume of Disease
3 year absolute OS point estimates to help patient counselling
o Relative risks are less ”intuitive” for patients
o High volume: ~ 20% absolute benefit.
o Very similar to docetaxel
o Low volume ~ 5% absolute OS.
Need longer term OS data to see if OS benefit is greater with early
use abiraterone
o Or are the indolent patients able to be salvaged with addition of
abiraterone at CRPC?
LATITUDE are all de novo & < 5% STAMPEDE relapsed after prior local
therapy
23
24. Current mHSPC OS with “Amides” by Volume of Disease
24
ENZAMET Primary Endpoint: Overall Survival
A Mixed Bag
High & Low Volume
De novo vs Metach
Mets
Concurrent Docetaxel
Many Permutations
25. Trial[1] Comparator Arm Control Arm N
HR for PFS (or Other
Endpoint)
HR for OS
Docetaxel
CHAARTED[2] ADT + Doc ADT 513 0.58 (time to CRPC) 0.63
GETUG-15[3] ADT + Doc ADT 183 NA 0.78
STAMPEDE Arm C[4] ADT + Doc ADT 148 NA 0.81
AR Pathway Inhibitors
LATITUDE[5] ADT + ABI + Pred ADT 955 NA 0.62
STAMPEDE Arm G[6] ADT + ABI + Pred ADT 473 0.31 (FFS) 0.54
ENZAMET[7] ADT + ENZA (± Doc) ADT + NSAA (± Doc) 588 0.45 0.80
ARCHES[8] ADT + ENZA* ADT* 727 0.43 (rPFS) TBD
TITAN[9] ADT + APA* ADT* 660 0.53 0.68
RT
STAMPEDE Arm H[10] ADT + RT to prostate ADT (+ DOC possible) 1120 NA 1.07
HORRAD[11] ADT + RT to prostate ADT 272 NA 1.06
Reported RCTs in mHSPC: High-Volume/High-Risk Disease
*Prior DOC allowed.
26. Local Treatment in Metastatic Prostate Cancer
HORRAD (N = 425)[1]
‒ ADT vs ADT + EBRT, ≥ M1a disease on conventional imaging
‒ At a median FU of 47 months no significant difference in median OS (43 vs 45 months)
STAMPEDE arm H (N = 2061)[2]
‒ ADT vs ADT + EBRT, ≥ M1a disease on conventional imaging
‒ For low volume disease OS HR = 0.68 (P = .007) vs 1.07 (P = .420) for high volume
disease
‒ At median FU of 37 months no OS improvement from local RT
Trials in progress: SWOG 1802 (NCT03678025), PEACE-1 (NCT01957436)
1. Boevé. Eur Urol. 2019;75:410-8. 2. Parker. Lancet. 2018;392:2353.
27. NCT01957436.
PEACE1: ADT vs ADT + Abiraterone, Local RT, or Both in
Newly Diagnosed Metastatic Prostate Cancer
Prospective, randomized
phase III multicenter trial
Primary endpoints:
OS and PFS (HR: 0.75)
Secondary endpoints: PSA
RR, safety, radiologic PFS
Patients with newly
diagnosed metastatic,
hormone-naive prostate
cancer; ECOG PS 0/1
(N = 1173)
ADT*
ADT* + Abiraterone 1000 mg/day PO +
Prednisone 5 mg BID
ADT* + Local RT (74 Gy in 37 fractions)
ADT* + Local RT (74 Gy in 37 fractions) +
Abiraterone 1000 mg/day PO +
Prednisone 5 mg BID
Upon
reaching
CRPC,
treatment
can include
abiraterone
if previously
received in
this trial
*Either LHRH agonist, LHRH antagonist, or surgical castration,
plus docetaxel 75 mg/m2/cycle x six 3-wk cycles
30. Hormone-Sensitive Metastatic Prostate Cancer: Big
Picture Issues
mHSPC is a heterogeneous disease state
‒ de novo vs recurrent metastatic disease
Compelling evidence that ADT + “X” is the standard of care (polymetastatic disease)
‒ Rare case indeed for ADT only therapy in 2020 and beyond but …
‒ A recent study found that 43% of patients with mHSPC receive ADT alone[1]
Role of local therapy in metastatic disease
Decision re: what is the optimal “X” therapy is not based on comparative trial
evidence, but requires consideration of multiple disease and non-disease factors
Germline testing is now standard of care for all metastatic patients
1. Ke. ASCO 2020. Abstr. e19131.
39. CARD Trial: Phase IV Trial of Cabazitaxel vs Abiraterone
or Enzalutamide in Previously Treated mCRPC
Primary endpoint: imaging-based PFS
Secondary endpoint: OS, PFS, PSA response, tumor response, time to SSE,
pain response, and safety
Patients with mCRPC
previously treated with
≥ 3 cycles of docetaxel and
disease progression after
≤ 12 mos on abiraterone or
enzalutamide (before or
after docetaxel)
(N = 255)
Until PD
Cabazitaxel 25 mg/m2 Q3W
+ Prednisone + G-CSF
(n = 129)
Enzalutamide 160 mg QD or
Abiraterone 1000 mg QD + Prednisone 5 mg BID
(n = 126)
Stratified by ECOG PS (0/1 vs 2), time to progression of prior
alternative ARTA (≤ 6 mos vs > 6-12 mos), timing of prior
AR-targeted therapy (before vs after docetaxel)
de Wit. NEJM. 2019;381:2506.
40. 50
Patients at Risk, n
Cabazitaxel
AR inhibitor
CARD: OS
de Wit. NEJM. 2019;381:2506.
Cabazitaxel
(n = 129)
AR Inhibitor
(n = 126)
Median OS, mos (95% CI) 13.6 (11.5-17.5) 11.0 (9.2-12.9)
HR 0.64 (95% CI: 0.46-0.89; P = .008)
Months
Cabazitaxel
AR Inhibitor
OS
(%)
Mos
100
90
80
70
60
40
30
20
10
0
30
0 3 6 9 12 18 24
129
126
122
116
96
88
77
64
51
39
21
11
8
3
2
0
41. 23% of metastatic castration-resistant prostate
cancers have DNA repair alterations[1]
Frequency of DNA repair alterations increases
with disease progression
DNA Repair Gene Alterations Are Common in Metastatic
Prostate Cancer
11.8% of 692 men with metastatic
prostate cancer had germline DNA repair
defects[2]
Not all men with germline mutations had
a family history of cancer
1. Robinson. Cell. 2015;161:1215. 2. Pritchard. NEJM. 2016;375:443.
Distribution of Presumed Pathogenic
Germline Mutations[2]
PALB2, 4%
RAD51D, 4%
ATR, 2%
NBN, 2%
PMS2, 2%
GEN1, 2%
MSH2, 1%
MSH6, 1%
RAD51C, 1%
MRE11A, 1%
BRIP1, 1%
FAM175A, 1%
BRCA2, 44%
ATM, 13%
CHEK2,
12%
BRCA1, 7%
42. Phase III PROfound: Olaparib vs Physician’s Choice in
Progressing mCRPC
*Enzalutamide 160 mg QD or abiraterone acetate 1000 mg QD plus prednisone 5 mg BID.
†BRCA1/2, ATM, BRIP1, BARD1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RA51D, or RAD54L.
Primary endpoint: radiographic PFS in cohort A by BICR using RECIST 1.1 and PCWG3
Secondary endpoints: radiographic PFS in both cohorts, confirmed radiographic ORR in cohort A,
time to pain progression in cohort A, OS in cohort A
de Bono. NEJM. 2020;382:2091.
Patients with mCRPC
and progression on
prior NHA; harboring
gene alterations with
a role in HRR†
(N = 387)
Olaparib 300 mg BID
(n = 162)
Physician’s Choice*
(n = 83)
2:1
Olaparib 300 mg BID
(n = 94)
Physician’s Choice*
(n = 48)
Cohort A: BRCA1,
BRCA2, or ATM
alterations
(n = 245)
Cohort B: Other
alterations
(n = 142)
2:1
Stratified by previous taxane (yes vs no) and
measurable disease (yes vs no)
PD
by BICR
PD
by BICR
Crossover allowed upon
progression on physician’s
choice therapy
43. PROfound: Final OS in Cohort A
Hussain. NEJM. 2020;[Epub].
Patients at Risk, n
Olaparib
Control
Mos
OS
(%)
Olaparib
(n = 162)
Control
(n = 83)
Median OS, mos 19.1 14.7
HR 0.69 (95% CI: 0.50-0.97; P = .02)
Cohort A: BRCA1, BRCA2, or ATM mutations
162
83
155
79
150
74
142
69
136
64
124
58
107
50
101
43
91
37
71
27
56
18
44
15
30
11
18
9
6
6
2
3
1
1
0
0
34
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32
100
90
80
70
60
50
40
30
20
10
0
91%
84%
73%
61%
54%
42%
Olaparib
Control
44. TRITON2: Rucaparib in Metastatic CRPC With HRR Gene
Alterations
International, multicenter, open-label phase II study
Abida. ESMO 2018. Abstr 793PD. Abida. JCO. 2020;[Epub].
Patients with mCRPC and deleterious
somatic or germline alteration in HRR
genes*; progression on AR-directed tx†
for PC and 1 prior line of taxane-based
CT for CRPC; no prior PARPi,
mitoxantrone, cyclophosphamide, or
platinum-based CT; ECOG PS 0/1
(N = 190‡)
Until radiographic
progression or
discontinuation for
other reason
Rucaparib 600 mg BID
in 28-d cycles§
Primary endpoints
‒ Among patients with measurable disease at BL: centrally assessed, confirmed ORR per modified
RECISTǁ/PCWG3
‒ Among patients without measurable disease at BL: locally assessed, confirmed PSA response
(≥ 50% decrease) rate
*Local or central testing of blood or tumor samples for alterations in HRR genes: BRCA1, BRCA2,
ATM, BARD1, BRIP1, CDK12, CHEK2, FANCA, NBN, PALB2, RAD51, RAD51B, RAD51C, RAD51D,
RAD54L.†Abiraterone, enzalutamide, or apalutamide. ‡Enrollment cutoff: February 28, 2019.
§Assessments: tumor Q8W for 24 wks, then Q12W; PSA Q4W.
45. PROpel Trial: First-line Olaparib + Abiraterone
Primary endpoints: radiographic PFS (rPFS) by investigator
Key secondary endpoints: OS, time to subsequent therapy or death; time to pain
progression
Randomized, double-blind, international, phase III study
Patients with progressing mCRPC;
no prior therapy for mCRPC;
docetaxel for mHSPC allowed;
ECOG PS 0/1; no prior
abiraterone
(planned N = 720)
Until radiographic progression or
unacceptable toxicity
Crossover from placebo to
olaparib not permitted
Olaparib 300 mg BID +
Abiraterone* 1000 mg qd
(n = 360)
Placebo +
Abiraterone* 1000 mg qd
(n = 360)
Stratified by metastatic disease (bone only vs
visceral vs other); docetaxel for mHSPC (yes vs
no)
* Prednisone/prednisolone (5 mg) given with abiraterone.
NCT03732820.
47. Theranostics: use of a compound for both diagnostics and therapeutics
Therapy:
Lu-177
Y-90
PSMA-I&T
Imaging:
Ga-68
Theranostics and PSMA Targeting
Schottelius. EJNMMI Res. 2015;5:68.
49. Primary endpoint: OS
Secondary endpoints: rPFS, RECIST response, time to first symptomatic skeletal event
Median follow-up: 12-14 mo (minimum: 15 mo)
Phase I/II PRINCE trial planned: Lu-PSMA + immunotherapy in mCRPC (NCT03658447)
VISION: Lu-PSMA vs Best Supportive Care in
Progressive, Metastatic CRPC
Randomized, ongoing phase III study at 9 sites in North America and Europe
ClinicalTrials.gov. NCT03511664.
Patients with
progressive CRPC; PSMA
positive; previous
treatment with taxane
and novel androgen
axis-targeted therapy
(N = > 750 recruited)
177Lu-PSMA-617
7.4 GBq IV Q6w
x 6 cycles + BSC/BSOC
Best Supportive Care /
Best Standard of Care
2:1
BSC/
BSOC
50. GSK2636771, a PI3Kβ inhibitor, in Pts with PTEN-
Deficient Tumors
Arkenau HT, et al. ASCO 2014. Abstract
2514.